We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
On Nov 13, we issued an updated research report on Donaldson Company, Inc. (DCI - Free Report) .
In the past three months, this Zacks Rank #3 (Hold) stock has rallied 16.1% compared with the industry’s increase of 10.5%.
Existing Scenario
Donaldson has been gaining from strong demand for its razor-to-sell razor-blade products and dust collection replacement parts, particularly in China. Product launches, new program wins and growing e-commerce business are likely to drive its revenues in the quarters ahead.
Also, the company is poised to boost its competency on the back of its ongoing capital expenditure and innovation investments. In this regard, its capital expenditure totaled $38 million in fourth-quarter fiscal 2019 (ended July 2019), up 66.7% year over year. These investments were made toward capacity expansion projects.
Further, the BOFA International acquisition (closed on Oct 22, 2018) has been strengthening the company's Industrial Products segment. For fiscal 2020 (ending July 2020), Donaldson expects the BOFA buyout to add $9-$10 million to sales growth at the industrial filtration solutions business.
However, the company seems concerned about the tough operating environment. For fiscal 2020, the company anticipates global equipment production to be down in the low to mid-single-digit range. For fiscal 2020, it predicts sales to be in the range of 2% decline to 4% increase compared with 4% growth recorded in fiscal 2019 (ended July 2019).
In addition, escalating costs have been a major cause of concern. For instance, Donaldson’s cost of sales jumped 5.5% in fiscal 2019, while the same rose 2.4% in the fiscal fourth quarter mainly due to higher supply-chain and raw material costs. We believe that rising costs and expenses, if unchecked, will be detrimental to the company's margins.
Albany International delivered average positive surprise of 21.27% in the trailing four quarters.
AZZ pulled off average positive surprise of 2.12% in the last four quarters.
Dover came up with average beat of 6.70% in the preceding four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Donaldson (DCI) Displays Solid Prospects, Headwinds Persist
On Nov 13, we issued an updated research report on Donaldson Company, Inc. (DCI - Free Report) .
In the past three months, this Zacks Rank #3 (Hold) stock has rallied 16.1% compared with the industry’s increase of 10.5%.
Existing Scenario
Donaldson has been gaining from strong demand for its razor-to-sell razor-blade products and dust collection replacement parts, particularly in China. Product launches, new program wins and growing e-commerce business are likely to drive its revenues in the quarters ahead.
Also, the company is poised to boost its competency on the back of its ongoing capital expenditure and innovation investments. In this regard, its capital expenditure totaled $38 million in fourth-quarter fiscal 2019 (ended July 2019), up 66.7% year over year. These investments were made toward capacity expansion projects.
Further, the BOFA International acquisition (closed on Oct 22, 2018) has been strengthening the company's Industrial Products segment. For fiscal 2020 (ending July 2020), Donaldson expects the BOFA buyout to add $9-$10 million to sales growth at the industrial filtration solutions business.
However, the company seems concerned about the tough operating environment. For fiscal 2020, the company anticipates global equipment production to be down in the low to mid-single-digit range. For fiscal 2020, it predicts sales to be in the range of 2% decline to 4% increase compared with 4% growth recorded in fiscal 2019 (ended July 2019).
In addition, escalating costs have been a major cause of concern. For instance, Donaldson’s cost of sales jumped 5.5% in fiscal 2019, while the same rose 2.4% in the fiscal fourth quarter mainly due to higher supply-chain and raw material costs. We believe that rising costs and expenses, if unchecked, will be detrimental to the company's margins.
Key Picks
Some better-ranked stocks from the Zacks Industrial Products sector are Albany International Corporation (AIN - Free Report) , AZZ Inc. (AZZ - Free Report) and Dover Corporation (DOV - Free Report) . All these companies carry a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Albany International delivered average positive surprise of 21.27% in the trailing four quarters.
AZZ pulled off average positive surprise of 2.12% in the last four quarters.
Dover came up with average beat of 6.70% in the preceding four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>-